Russia Successfully Completes Testing of Its COVID-19 Vaccine

The clinical tests of the COVID-19 vaccine developed by the National Center for Epidemiological Research and Microbiology “Gamalei” of Russia have concluded and registration stage begins, reported today the Russian Minister of Health, Mikhail Murashko.

“The vaccine against the new coronavirus developed by the Gamalei center has completed clinical trials and documents are now being prepared for registration,” said Murashko, quoted by TASS.

According to the Health Minister, doctors and teachers will be the first to receive this vaccine, and it is planned that from next August 10 it will be sent to the Russian regions.

“We plan that the broader vaccination campaign, which will gradually be added to the new care system, begin in October,” he said.

The minister added that the second russian vaccine, developed by the Véctor center, is currently in the process of clinical tests and stated that the Ministry of Health expects “in the next month and a half or two months” to receive two other requests for permission to carry out clinical tests of new vaccines .

The day before, the leading epidemiologist in the United States, Anthony Fauci, said he hopes China and Russia “are really testing” vaccines against COVID-19 that they develop “before administering it to someone”.

Fauci made these remarks after Russian authorities indicated the upcoming approval of the vaccine against the new coronavirus, Anticipating the United States.

Russia records a slight improvement in the pandemic situation in COVID-19. Since last July 20 the number of new infections has remained below 6,000 and today only 95 deaths have been reported, 66 fewer than the previous day.

During the last day, 5,462 new cases were reported, 1,356 (24.8%) asymptomatic, while 8,114 patients were discharged.

Since the pandemic began, 845,443 people have fallen ill in Russia and 14,058 have died, which places it in fourth place worldwide by number of infections, surpassed by the United States, Brazil and India